JOURNAL OF CLINICAL ONCOLOGY

Evaluation of a Pharmacist-Led Medication Assessment Used to Identify Prevalence of and Associations With Polypharmacy and Potentially Inappropriate Medication Use Among Ambulatory Senior Adults With Cancer

Ginah Nightingale, Emily Hajjar, Kristine Swartz, Jocelyn Andrel-Sendecki, and Andrew Chapman

See accompanying editorial on page 1422

A B S T R A C T

Purpose

The use of multiple and/or inappropriate medications in seniors is a significant public health problem, and cancer treatment escalates its prevalence and complexity. Existing studies are limited by patient self-report and medical record extraction compared with a pharmacist-led comprehensive medication assessment.

Patients and Methods

We retrospectively examined medication use in ambulatory senior adults with cancer to determine the prevalence of polypharmacy (PP) and potentially inappropriate medication (PIM) use and associated factors. PP was defined as concurrent use of five or more and less than 10 medications, and excessive polypharmacy (EPP) was defined as 10 or more medications. PIMs were categorized by 2012 Beers Criteria, Screening Tool of Older Person's Prescriptions (STOPP), and the Healthcare Effectiveness Data and Information Set (HEDIS).

Results

A total of 248 patients received a geriatric oncology assessment between January 2011 and June 2013 (mean age was 79.9 years, 64% were women, 74% were white, and 87% had solid tumors). Only 234 patients (evaluated by pharmacists) were included in the final analysis. Mean number of medications used was 9.23. The prevalence of PP, EPP, and PIM use was 41% (n = 96), 43% (n = 101), and 51% (n = 119), respectively. 2012 Beers, STOPP, and HEDIS criteria classified 173 occurrences of PIMs, which were present in 40%, 38%, and 21% of patients, respectively. Associations with PIM use were PP (P < .001) and increased comorbidities (P = .005).

Conclusion

A pharmacist-led comprehensive medication assessment demonstrated a high prevalence of PP, EPP, and PIM use. Medication assessments that integrate both 2012 Beers and STOPP criteria and consider cancer diagnosis, prognosis, and cancer-related therapy are needed to optimize medication use in this population.

J Clin Oncol 33:1453-1459. © 2015 by American Society of Clinical Oncology

INTRODUCTION

The American Cancer Society estimates that by the year 2030, 70% of all cancers in United States will be diagnosed in senior adults.¹ The multiple layers of specialists (ie, oncologists, radiation oncologists, surgeons, geriatricians), primary care, and allied health professionals in the continuum of care makes this population a challenge to manage. Older adults with cancer are particularly prone to medication errors attributed to medication changes, complex regimens, and incomplete information handoff between providers.^{2,3} Polypharmacy (PP) and poten-

tially inappropriate medication (PIM) use warrant substantial interest and concern on behalf of medical oncologists and oncology health providers because of the perils associated with their use in this vulnerable population; vulnerabilities include increased risk of falls and/or fractures, cognitive impairment, and delirium, all of which can lead to compromised cancer management plans (eg, treatment delays and/or premature treatment discontinuation). Cancer-related therapy adds to the prevalence of the use of multiple medications and/or the consumption of inappropriate medications because new medications escalate their prevalence and

Ginah Nightingale and Emily Hajjar, Jefferson School of Pharmacy; Kristine Swartz and Andrew Chapman, Thomas Jefferson University Hospital; and Jocelyn Andrel-Sendecki, Thomas Jefferson University, Philadelphia, PA.

Published online ahead of print at www.jco.org on March 23, 2015.

Supported by an American Association of Colleges of Pharmacy 2013 New Investigator Award Grant (G.N., principal investigator and award recipient).

The sponsor did not play any role in the design or conduct of the study including data collection, management, analysis, interpretation of the data or preparation, review, or approval of the manuscript.

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Corresponding author: Ginah Nightingale, PharmD, BCOP, Jefferson School of Pharmacy, Thomas Jefferson University, 901 Walnut St, Suite 946, Philadelphia, PA 19107; e-mail: ginah.nightingale@ jefferson.edu.

© 2015 by American Society of Clinical Oncology

0732-183X/15/3313w-1453w/\$20.00

DOI: 10.1200/JCO.2014.58.7550

© 2015 by American Society of Clinical Oncology 1453

Information downloaded from jco.ascopubs.org and provided by at THOMAS JEFFERSON UNIVERSITY on August 10, Copyright © 2015 America0156/collar0/2880/n6ology. All rights reserved.

Characteristic	No.	%
Age, years		
Mean		.91
SD		.84
Range	61	-98
Age range, years		
60-69	16	6
70-79	91	37
80-89	122	49
90-99 Sex	19	8
Female	159	64
Male	89	36
Race/ethnicity	00	00
White	184	74.2
African American	48	19.4
Asian	9	3.6
Hispanic	6	2.4
Other	1	0.4
Cancer type		
Solid malignancies		
Colorectal	46	19
Breast	45	18
Lung*	39	16
Urinary tract (bladder, renal, urethral, urothelial)	18	7.3
Upper GI (pancreatic, bile duct, gall bladder)	15	6
Esophageal	9	3.6
Neuroendocrine	8	3.2
Gastric	7	2.8
Prostate	7	2.8
Sarcoma	6	2.4
Head and neck*	5	2
Gynecologic	5	2
Duodenal	2	0.8
Melanoma/skin cancer	2	0.8
Unknown primary	2	0.8
Mesothelioma	1	0.4
Hematologic malignancies	10	
Lymphoma	13	5.2
Myeloma	8	3.2
	5	2
Myelodysplastic syndrome	2	0.8
Other Polycythemia vera	2	0.8
Amyloidosis	2	0.8
Waldenström macroglobulinemia	1	0.4
Cancer stage		0.4
0	4	1.6
1	31	12.5
	59	23.8
III	46	18.6
IV	65	2.6
Unknown	1	0.4
Recurrence		
Local	5	2
Metastatic	29	11.7
Staging not applicable	8	3.2
Functionality status†		
Fit	57	23.3
Vulnerable	120	49
Frail	68	27.8
(continued in next column)		

Comorbidity count Mean SD ECOG performance score (n = 247) 0	7.0 3.4	
SD ECOG performance score (n = 247)		
ECOG performance score (n = 247)	3.4	47
0		
0	71	29
1	108	44
2	58	23
3	9	4
4	1	0.4

 \pm Functionality status (n = 245).

Functionality status (II -2^2

complexity, which consequently increases the risk for adverse drug effects, drug-drug interactions, and nonadherence as a result of increased pill burden and regimen complexity.⁴⁻⁸ Increased pill burden increases the risk of drug-drug, drug-food, and drug-herbal interactions, and medical oncologists may not know how to manage such issues.

A comprehensive medication review is considered to be an integral part of the geriatric oncology assessment.^{9,10} Extermann et al⁹ and the National Comprehensive Cancer Network Older Adult Oncology Guidelines¹⁰ both recommend a comprehensive medication assessment, which includes a thorough a review of patients' medications with subsequent discontinuation of any nonessential medications and evaluation for drug interactions, adverse effects, and patient adherence; however, such guidelines do not state which health care professional should be performing the medication assessment. Existing studies that report on the prevalence of PP and PIM use, specifically in ambulatory senior adults with cancer, report the prevalence of PP as 48% to 80% and PIM use as 8% to 41%. These studies are scarce and are limited by antiquated criteria and/or screening tools for defining PP and PIM use, and excessive polypharmacy (EPP) has never been examined.¹¹⁻¹⁴ In addition, the methodologies used in previous studies were flawed by the inherent pitfalls in measuring medication use by using patient self-reports and medical records extraction compared with using a pharmacist-led comprehensive medication assessment, which should be recognized as a best practice benchmark. On that basis, we designed this study to examine the prevalence of PP, EPP, and PIM use and factors influencing their use on the basis of a pharmacist-led comprehensive medication assessment in ambulatory senior adults with cancer at our institution.

PATIENTS AND METHODS

This protocol was approved by the institutional review board at our institution before initiation. This was a retrospective study (data were collected from physicians' and clinical pharmacists' electronic progress notes documented in the electronic medical record). All patients who received an initial geriatric oncology assessment at our senior adult oncology ambulatory center between January 2011 and June 2013 and had a diagnosis of cancer (all cancer types and all cancer stages) were included in the study. Our center is an outpatient ambulatory center that provides half-day services (5 hours) twice per week at two sites within the health care system. The core Older Adult Oncology

1454 © 2015 by American Society of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

Information downloaded from jco.ascopubs.org and provided by at THOMAS JEFFERSON UNIVERSITY on August 10, Copyright © 2015 Americ201 Society1eff7Cli#0c2850n6ology. All rights reserved.

multidisciplinary team consisted of a medical oncologist, geriatrician, patient navigator, clinical pharmacist, social worker, and a registered dietician.

As a standard of care at our center, patients were instructed to bring in all medications (prescription, nonprescription, herbals, and supplements) for the pharmacist-patient session. During the session, the pharmacist evaluated each medication with the patient and/or caregiver to confirm medication possession and/or self-administration, indication, and adverse effects; in addition, the pharmacist assessed the patient's ability to read medication label directions and to manage medications in an organized manner. The pharmacist provided medication-related education, addressed medication-related problems with the patient and the interdisciplinary health care team, updated the medication record, and documented a progress note in the electronic medical record. The pharmacist's medication-related recommendations (eg, discontinuation of unnecessary and/or inappropriate medications, recommendation of alternatives) were part of the comprehensive assessment and were forwarded to the primary oncologist and/or medical provider for evaluation and follow-up. PP was defined as concurrent use of five or more and less than 10 medications, and EPP was defined as concurrent use of 10 or more medications, including prescription, nonprescription, herbal, and supplement medications.¹⁵⁻¹

PIM use was categorized on the basis of three screening tools, including the 2012 Beers criteria, the Screening Tool of Older Person's Prescriptions (STOPP) criteria, and the Healthcare Effectiveness Data and Information Set (HEDIS) criteria for drugs to avoid in the elderly.¹⁹⁻²³ These three screening tools were used in this study because they represent the most current, evidence-based, clinically validated criteria in the literature. There is no head-to-head trial that recommends the use of one screening tool over another, so each of these tools is considered a viable option for use in clinical practice. The 2012 Beers criteria is the screening tool used in clinical practice in the United States and is supported and endorsed by the American Geriatrics Society. The STOPP criteria is a European screening tool developed on the basis of expert consensus and evidence-based criteria, and it incorporates commonly encountered instances of potentially inappropriate prescribing in senior adults, and it includes drug-drug and drug-disease interactions, drugs that adversely affect seniors at risk of falls, and duplicate drug class prescriptions. HEDIS is a health care quality measure used in the United States that was created by the National Committee on Quality Assurance to examine the quality of prescribing for older patients. The American Geriatrics Society stated that the STOPP criteria should be used in a complementary manner with 2012 Beers criteria to guide clinicians in making decisions about safe medication use in senior adults, largely because there are some notable differences between these screening tools.

Demographic and clinical patient information was collected from medical records and included age, sex, race, cancer type and cancer stage, comorbidities (number and type), and Eastern Cooperative Oncology Group (ECOG) performance status²⁴ and functional status by using stages of aging described as fit, vulnerable, or frail as determined by the geriatrician. Balducci et al²⁵ defined "fit" patients as those who lacked serious comorbidity and were functionally independent without evidence of geriatric syndromes. "Vulnerable" patients were dependent in one or more instrumental activities of daily living and had several more significant comorbid conditions. "Frail" patients were dependent in activities of daily living, had evidence of geriatric syndromes, and had significant comorbidities. PP and PIM factors that influenced or were associated with age, sex, PP, comorbidities, ECOG performance status, and functional status were analyzed. Descriptive statistics were calculated by using Fisher's exact test, Pearson's χ^2 test for categorical variables, Wilcoxon's test for continuous variables, and the Kruskal-Wallis test for assessments between groups.

RESULTS

Data were collected from 248 consecutive patients who received an initial geriatric oncology assessment at our institution between January 2011 and June 2013. The mean age was 80 years, 159 patients (64%) were women, and the mean number of comorbidities was 7.69

(excluding primary cancer). Two hundred sixteen patients (87%) had solid tumors, and 32 patients (13%) had hematologic malignancies. A majority with solid tumors had advanced-stage or metastatic disease. Table 1 displays the distribution of patients' baseline characteristics and Table 2 identifies patient characteristics by comorbidity type. Of the 248 patients evaluated at our center, 234 (94%) were seen by a clinical pharmacist for a comprehensive medication assessment and were included in the final analysis (the remaining 14 patients were evaluated on days on which pharmacist coverage was not readily available). Evaluation of the 234 patients by a clinical pharmacist

Table 2. Prevalence of Comorbidities by	Disease Status (n =	248)
Comorbidity	No.	%
Cardiovascular	230	92.7
Hypertension	187	75.4
Dyslipidemia	147	59.3
Arrhythmias	58	23.4
Congestive heart failure	51	20.6
Coronary artery disease	43	17.3
Stroke	40	16.1
Venous thromboembolism	26	10.5
Ischemic heart disease	12	4.8
Endocrine	117	47.2
Diabetes	77	31.1
Thyroid disease	62	25
Respiratory	88	35.5
Chronic obstructive pulmonary disease	56	22.6
Asthma	18	7.3
GI	108	43.6
Gastroesophageal reflux	68	27.4
Constipation/diarrhea	36	14.5
Peptic ulcer	21	8.5
Irritable bowel syndrome	12	4.8
Renal	43	17.3
Chronic kidney disease	33	13.3
Electrolyte disorders	4	1.6
Neurologic	89	35.9
Pain management	63	25.4
Alzheimer's disease	25	10.1
Epilepsy	5	2
Headache	4	1.6
Psychiatric	91	36.7
Anxiety	58	23.4
Depression	54	21.8
Sleep disorder	15	6.1
Schizophrenia	4	1.6
Urologic	68	27.42
Benign prostatic hypertrophy	32	12.9
Urinary incontinence	42	16.94
Rheumatologic	162	65.32
Osteoarthritis	102	51.2
Osteoporosis	61	24.6
Gout	15	6.1
Rheumatoid arthritis	4	1.6
	68	27.4
Ophthalmic Cataract		27.4
Glaucoma	68	
	28	11.3
Macular degeneration	13	5.2
Hematologic	82	33.1
Anemia	82	33.1

© 2015 by American Society of Clinical Oncology 1455

Pharmacologic Category	Prescription Medication	No.	%
Cardiovascular	Alpha-adrenergic agonists/antagonists, antiarrhythmics, beta-adrenergic antagonist, calcium channel antagonists, digoxin, renin-angiotensin aldosterone antagonists, vasodilators	180	76.9
Dislipidemics	Statins, ezetimibe, niacin, fenofibrate, colesevelam	124	53
GI	Antiemetics, antispasmodics, constipation/diarrhea, histamine-2 antagonist, protectants, irritable bowel syndrome, proton pump inhibitors	96	41
Diuretic		94	40.2
Endocrine	Antidiabetic oral/injectable, thyroid replacement, antithyroid agents	87	37.2
Analgesic	Nonsteroidal anti-inflammatory drugs, opioids/nonopioids, neuropathic pain drugs, topical anesthetics	69	29.5
Antiplatelet/anticoagulant		53	22.7
Neuropsychiatric	Antidepressants, anti-Parkinson agents, antipsychotics, anticonvulsants	51	21.8
Vitamin/minerals		45	19.2
Pulmonary/respiratory	Inhalers, oral tablets	44	18.8
Genitourinary		40	17.1
Benzodiazepine/barbiturate		39	16.7
Ophthalmic		31	13.2
Antimicrobial	Antibacterials, antifungals, antivirals	22	9.4
Bone health	Bishphosphonates (oral), parathyroid hormone analog, calcium, vitamin D agent	20	8.6
Glucocorticoid		17	7.3
Gout		11	4.7
Sedative hypnotic		10	4.3
Hormonal	Hormonal estrogens, androgens	8	3.4
Dermatologic topicals		5	2.1
Anti-neoplastic	Oral antineoplastics including conventional, targeted agents	4	1.7
Central nervous system stimulant		1	0.4
Otic		1	0.4

showed that they took 2,163 total medications, 1,430 prescription medications, 647 nonprescription medications, and 86 herbal medications. The mean number of medications used by patients was 9.23 (standard deviation [SD], 4.79; range, 1 to 30 medications). The medications were as follows: 6.1 prescription medications (SD, 3.58; range, 0 to 20 prescription medications), 2.76 nonprescription medications (SD, 2.11; range, 0 to 10 nonprescription medications), and 0.38 herbal medications (SD, 0.88; range, 0 to 10 herbal medications;). The prevalence of PP, EPP, and PIM use was 41%, 43%, and 51%, respectively. Table 3 shows that the most common prescription medications were drugs that act on the cardiovascular system at a prevalence of 77%, dyslipidemics at 53%, GI medications at 41%, diuretic medications at 40%, and endocrine-related medications at 37%. Appendix Table A1 (online only) lists comorbidity types associated with PP category.

2012 Beers, STOPP, and HEDIS criteria classified 173 occurrences of PIMs present in 40% (n = 94), 38% (n = 88), and 21% (n = 49) of patients, respectively. BEERs and STOPP criteria were most inclusive, each detecting 118 occurrences, and HEDIS detected 58 occurrences (of 173 occurrences). Mutual overlap between Beers and STOPP criteria occurred in 38% of PIM use (66 of 173 occurrences). The mean number of inappropriate medications used by patients was 0.74 (SD, 0.89; range, 0 to 4 inappropriate medications). The proportion of study participants who were prescribed 0, 1, 2, 3, and 4 PIMs was 49%, 34%, 12%, 4%, and 1%, respectively. The most prevalent PIMs are listed in Table 4 and include benzodiazepines (16%), GI medications (9.4%), nonsteroidal anti-inflammatory drugs (8.5%), antiplatelet medications (8%), and first-generation antihistamines (6%). The most common medications detected by 2012 Beers (but not by STOPP) criteria were short- and intermediate-acting benzodiazepines and sedative hypnotics. The most common medications detected by STOPP (but not by 2012 Beers) criteria were antiplatelet medications (specifically, aspirin at doses above 150 mg per day), beta-blockers (noncardioselective beta-blocker with chronic obstructive pulmonary disease), and proton pump inhibitors (for peptic ulcers at the full therapeutic dose for more than 8 weeks). In Table 5, patient characteristics associated with PP were increased number of comorbidities, increased PIM use, reduced ECOG performance status at baseline, and reduced functional status at baseline. Patient characteristics associated with PIM use (ν no PIMs) were PP (P < .001) and increased number of comorbidities (P = .005), as listed in Table 6. Specific comorbidities that were associated with PIM use were cardiovascular (P = .014), GI (P = .013), neurologic (P =.020), and psychiatric (P < .001) conditions, as summarized in Appendix Table A2 (online only). The rate of PIM use differs between PP categories, as illustrated in Appendix Figure A1 (online only). The mean number of PIMs used between no PP, PP, and EPP is 0.19, 0.6, and 1.07, respectively. The PIM use rate between no PP and PP is 6% versus 9% (P < .001).

DISCUSSION

In this cohort of senior adult oncology patients, a pharmacist-led medication assessment identified a high prevalence of PP, EPP, and PIM use compared with previously reported methodologies. Studies reporting on the prevalence of PP and PIM use, specifically in ambulatory older adults with cancer, are limited. Lichtman et al¹¹ published an abstract on PIM use in older patients with cancer in the outpatient setting. The investigation identified PIM use in 11% of patients on the

JOURNAL OF CLINICAL ONCOLOGY

Information downloaded from jco.ascopubs.org and provided by at THOMAS JEFFERSON UNIVERSITY on August 10, Copyright © 2015 Ameri@20156rciety14f7Cli#0c2880n6ology. All rights reserved.

Pharmacologic Category	PIMs	No.	%
Benzodiazepine		38	16.2
GI	Antiemetics, anticholinergic/antispasmodics, constipation/diarrhea, proton pump inhibitors	22	9.4
Nonsteroidal anti-inflammatory drugs		20	8.6
Antiplatelet		19	8.1
Antihistamine		14	6
Beta-adrenergic antagonist		13	5.6
Sedative hypnotic		7	3
Neuropsychiatric	Antipsychotics	6	2.6
Cardiovascular	Antiarrhythmics, calcium channel antagonists	6	2.6
Endocrine	Long-acting sulfonylureas, sliding-scale insulin, dessicated thyroid	6	2.6
Diuretic	Hydrochlorothiazide	4	1.7
Hormonal	Conjugated estrogens, megesterol	4	1.7
Muscle relaxant		2	0.9
Antibiotic	Nitrofurantoin	1	0.4
Anticholinergic	Benztropine	1	0.4
CNS stimulant		1	0.4
Genitourinary	Oxybutinin	1	0.4

basis of 2003 Beers criteria, and the median number of medications used was 8 (range, 0 to 23 medications). Maggiore et al¹² published an abstract on PP, PIM use, and chemotherapy-related adverse events among older adults with cancer. That study evaluated 500 patients

with a mean age of 73 years, and the mean number of daily medications used was five. The prevalence of PP was 48% (239 of 500), and the prevalence of PIM use ranged from 11% (53 of 500) to 18% (89 of 500), depending on the tool used to classify PIM use (2003 Beers criteria

	med	PP (< 5 cations) = 37)	medi	PP (≥ 5 cations) = 197)		medi	≥ 5 and < 10 cations) = 96)	medi	P (≥ 10 ications) = 101)	
Characteristic	No.	%	No.	%	Р	No.	%	No.	%	Ρ
Age, years					.491					.397
Mean	7	9.03	7	9.93		8	0.34	7	9.53	
SD		7.4	6	6.65		7	.32	Ę	5.95	
Sex					.265					.986
Female	27	72.97	123	62.44		60	62.5	63	62.38	
Male	10	27.03	74	37.56		36	37.5	38	37.62	
Race/ethnicity					.861					.109
White	25	67.57	148	75.13		67	69.79	81	80.2	
African American	9	24.32	36	18.27		18	18.75	18	17.82	
Asian	2	5.41	7	3.55		6	6.25	1	0.99	
Hispanic	1	2.70	5	2.54		4	4.17	1	0.99	
Other	0	0.00	1	0.51		1	1.04	0	0	
Functional status (n = 232)					< .001					< .00
Fit	21	58.33	33	16.84		25	26.32	8	7.92	
Frail	3	8.33	60	30.61		22	23.16	38	37.62	
Vulnerable	12	33.33	103	52.55		48	50.53	55	54.46	
No. of comorbidities					< .001					< .00
Mean	4	.59	8	3.60		7	.21	ç	9.93	
SD	4	2.19	3	3.40		2	.86	3	3.36	
Median		5		8			6		6	
Range		-10	2	2-21		2	-15	3	3-21	
PIM use	7	18.92	112	56.85	< .001	42	43.75	70	69.31	< .00
ECOG performance status (n = 233)					.005					.048
0-1	34	91.89	136	69.39		73	76.04	63	63	
2-4	3	8.11	60	30.61		23	23.96	37	37	

Abbreviations: ECOG, Eastern Cooperative Oncology Group; EPP, excessive polypharmacy; PIM, potentially inappropriate medication; PP, polypharmacy; SD, standard deviation.

© 2015 by American Society of Clinical Oncology 1457

		9 PIM = 115)		PIM = 119)	
Characteristic	No.	%	No.	%	Ρ
Age, years					.26
Mean	8	30.3	7	79.3	
SD		7.2		6.3	
Sex					.53
Female	76	66	74	62	
Male	39	34	45	38	
Race/ethnicity					.43
White	80	70	93	78	
African American	24	21	21	18	
Asian	6	5	3	3	
Hispanic	4	3	2	2	
Other	1	0.8	0		
Eunctional status (n = 232)					.09
Fit	33	29	21	17	
Frail	26	23	37	31	
Vulnerable	55	48	60	51	
PP					< .00
None	30	26.09	7	5.88	
PP	54	46.96	42	35.29	
EPP	31	26.96	70	58.82	
No. of comorbidities					.00
Mean	7	7.26	8	3.66	
SD	:	3.4		3.6	
Median		7		8	
Range	1	-16	2	2-21	
ECOG performance status (n = 233)					.36
0-1	87	76	83	70	
2-4	28	24	35	30	

Abbreviations: ECOG, Eastern Cooperative Oncology Group; EPP, excessive polypharmacy; PIM, potentially inappropriate medication; PP, polypharmacy; SD, standard deviation.

or 2001 Zhan criteria). In 2013, Maggiore et al¹⁴ published a modified abstract on PIM use and chemotherapy-related adverse events using the 2012 Beers criteria. The prevalence of PIM use ranged from 11% to 29%, depending on the tool used to classify PIM use (2001 Zhan criteria or 2012 Beers criteria). Prithviraj et al¹³ evaluated patient characteristics associated with PP and inappropriate prescribing of medications among older adults with cancer, which included 117 patients with a mean age of 74.6 years. The mean number of daily medications was 7.3, the prevalence of PP was 80%, and the prevalence of PIM use was 41% (2003 Beers criteria). Finally, a study by Sokol et al²⁶ retrospectively evaluated medication use in senior adults with cancer (mean age, 79 years) at a large community oncology facility in an academic practice setting. Sokol et al identified a mean number of 9.1 medications used by patients in their cohort; however, the majority of patients were receiving concurrent chemotherapeutic agents. PIM use was not reported.

Our study shows a mean number of 9.2 medications used by the cohort, 41% prevalence of PP, and 43% prevalence of EPP, which is slightly higher than in previous publications. The reduced prevalence of PP reported by previous publications may be associated with the fact that previous investigations were based on antiquated criteria and/or screening tools for defining PP and PIM use in the elderly, and EPP was not defined or examined in any of these studies. The majority of these investigations assessed medications and medication use on the

basis of usual care standards, defined as physician- or prescriberdirected medication assessments documented in medical records and/or medication databases compared with a pharmacist-directed comprehensive medication assessment, which may explain a higher prevalence of PP in our study compared with that in previous publications. Similarities between 2012 Beers and STOPP criteria include nonsteroidal anti-inflammatory drugs, tricyclic antidepressant medications, and long-acting benzodiazepine medications. Differences include items in the STOPP criteria such as the use of noncardioselective beta blockers in chronic obstructive pulmonary disease, the use of aspirin at dosages greater than 150 mg per day, and the use of proton pump inhibitors for treatment durations of greater than 8 weeks, which are not included in 2012 Beers criteria. The American Geriatrics Society highlights the notion that the STOPP criteria be used in a complementary manner with 2012 Beers criteria to guide clinicians in making decisions about safe medication use in senior adults. This recommendation is accurate and is reinforced by the fact that in our study, there was insufficient overlap between the 2012 Beers and STOPP criteria, because both tools combined mutually identified 66 (38%) occurrences of PIM use, further supporting the fact that use of both tools may be seen as complementary.

In this study, patient characteristics associated with PP (ν no PP) were increased number of comorbidities (P < .001), increased PIM use (P < .001), reduced ECOG performance status at baseline (P = .005), and reduced functional status at baseline (P < .001). Prithviraj et al¹³ found that patients who were taking five or more medications (compared with < 5 concurrent medications) were statistically significantly more likely to have poor functional status, have five or more comorbidities, and be prescribed a PIM per 2012 Beers criteria. The authors found an association between medication use and ECOG performance scores, with patients taking multiple medications more likely to have poorer performance status, which was also found in our study. Finally, our study found associations between PIM use (ν no PIM use) and PP (P < .001) and increased number of comorbidities (P = .005), specifically cardiovascular, GI, neurologic, and psychiatric conditions.

To the best of our knowledge, our study is the first of its kind to incorporate a pharmacist-led comprehensive medication assessment using the most current, evidence-based, clinically validated criteria and screening tools to examine the prevalence of PP, EP, and PIM use in this complex population. Studies show that when pharmacists are involved in care transitions and take measures to decrease the prevalence of multiple medication use and medication-related problems, hospital readmission rates and preventable adverse drug events are reduced; however, these studies are mostly limited to the inpatient setting in the area of medication reconciliation and discharge programs.^{3,27-33} Although these inpatient programs provide a robust framework, identifiable gaps exist because the literature does not focus on the ambulatory care setting or the oncology population. Integrating clinical pharmacy services in this multidisciplinary team may have the potential to optimize patient medication use and health outcomes by providing comprehensive medication assessment and planning (for both oncology and medicine issues), all before initiating cancer and/or supportive care treatment.

This study has some shortcomings that limit its clinical applicability to the larger population. This was a single-institution study with a small sample size compared with some previous studies. Medication use was assessed at a single (initial) visit in which most patients were

JOURNAL OF CLINICAL ONCOLOGY

not receiving any anticancer treatments or cancer-related therapies. Medication use in this population changes continuously, especially for the patients who will begin anticancer and/or supportive care–related therapies, so follow-up data on acceptance of pharmacist interventions would strengthen study findings. Finally, patient outcomes associated with excessive and inappropriate medication use—increased use of health care resources (eg, hospitalizations) and adverse events that compromised cancer management plans—were not captured.

A pharmacist-led comprehensive Older Adult Oncology medication assessment demonstrated a high prevalence of PP, EPP, and PIM use versus previously reported methodologies. The prevalence of PIMs varied depending on the screening tool applied, yet the 2012 Beers criteria detected the highest prevalence of PIM use in this population. Because of the minimal overlap between 2012 Beers and STOPP criteria, a modified PIM tool that integrates 2012 Beers and STOPP criteria and considers cancer diagnosis, prognosis, and cancer-related therapy is needed to identify and minimize PIM use. Additional follow-up studies are needed to longitudinally evaluate medication use to identify

REFERENCES

 Smith BD, Smith GL, Hurria A, et al: Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 27:2758-2765, 2009

2. Vira T, Colquhoun M, Etchells E: Reconcilable differences: Correcting medication errors at hospital admission and discharge. Qual Saf Health Care 15:122-126, 2006

3. Coleman EA, Smith JD, Raha D, et al: Posthospital medication discrepancies: Prevalence and contributing factors. Arch Intern Med 165:1842-1847, 2005

 Riechelmann RP, Tannock IF, Wang L, et al: Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592-600, 2007

5. Riechelmann RP, Zimmermann C, Chin SN, et al: Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 35:535-543, 2008

 Riechelmann RP, Moreira F, Smaletz O, et al: Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56:286-290, 2005

 Puts MT, Costa-Lima B, Monette J, et al: Medication problems in older, newly diagnosed cancer patients in Canada: How common are they? A prospective pilot study. Drugs Aging 26:519-536, 2009

8. Scripture CD, Figg WD: Drug interactions in cancer therapy. Nat Rev Cancer 6:546-558, 2006

9. Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824-1831, 2007

10. National Comprehensive Cancer Network: The NCCN Clinical Practice Guidelines in Oncology, Older Adult Oncology (version 2015). www.NCCN.org

11. Lichtman SM, Boparai MK. Geriatric medication management: Evaluation of pharmacist interventions and potentially inappropriate medication (PIM) use in older (> 65 years) cancer patients. J Clin Oncol 27:484s, 2009 (suppl; abstr 9507)

associations with increased risk of adverse events that compromise cancer management plans and worsen patient outcomes in this complex and vulnerable population.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at www.jco.org.

AUTHOR CONTRIBUTIONS

Conception and design: Ginah Nightingale, Emily Hajjar, Kristine Swartz, Andrew Chapman Collection and assembly of data: Ginah Nightingale, Emily Hajjar, Andrew Chapman Data analysis and interpretation: Ginah Nightingale, Jocelyn Andrel-Sendecki Manuscript writing: All authors Final approval of manuscript: All authors

12. Maggiore RJ, Gross CP, Hardt M, et al: Polypharmacy, potentially inappropriate medications, and chemotherapy-related adverse events among older adults with cancer. J Clin Oncol 29, 2011 (suppl; abstr e19501)

13. Prithviraj GK, Koroukian S, Margevicius S, et al: Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol 3:228-237, 2012

 Maggiore RJ, Feng T, Dale W, et al: Measures of polypharmacy and chemotherapy toxicity in older adults with cancer. J Clin Oncol 31, 2013 (suppl 15s; abstr 9545)
Stewart RB: Polypharmacy in the elderly: A

fait accompli? DICP 24:321-323, 1990 **16.** Montamat SC, Cusack B: Overcoming prob-

lems with polypharmacy and drug misuse in the elderly. Clin Geriatr Med 8:143-158, 1992

17. Hajjar ER, Cafiero AC, Hanlon JT: Polypharmacy in elderly patients. Am J Geriatr Pharmacother 5:345-351, 2007

18. Hovstadius B, Petersson G: Factors leading to excessive polypharmacy. Clin Geriatr Med 28:159-172, 2012

19. Gallagher P, O'Mahony D: STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): Application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing 37:673-679, 2008

20. O'Mahony D, Gallagher P, Ryan C, et al: STOPP & START criteria: A new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatr Med 1:45-51, 2010

21. Hamilton H, Gallagher P, Ryan C, et al: Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 171:1013-1019, 2011

22. National Committee on Quality Assurance: Drugs to be avoided in the elderly. December 11, 2011

23. American Geriatrics Society 2012 Beers Criteria Update Expert Panel: American Geriatrics Society updated Beers Criteria for potentially inappropriate

medication use in older adults. J Am Geriatr Soc 60:616-631, 2012

24. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982

25. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 5:224-237, 2000

26. Sokol KC, Knudsen JF, Li MM: Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 32:169-175, 2007

27. Walker PC, Bernstein SJ, Jones JN, et al: Impact of a pharmacist-facilitated hospital discharge program: A quasi-experimental study. Arch Intern Med 169:2003-2010, 2009

28. Schnipper JL, Kirwin JL, Cotugno MC, et al: Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med 166:565-571, 2006

29. Thompson CA: High-risk patients benefit from clinical pharmacy services collaborative. Am J Health Syst Pharm 68:465, 2011

30. Setter SM, Corbett CF, Neumiller JJ, et al: Effectiveness of a pharmacist-nurse intervention on resolving medication discrepancies for patients transitioning from hospital to home health care. Am J Health Syst Pharm 66:2027-2031, 2009

31. Murphy EM, Oxencis CJ, Klauck JA, et al: Medication reconciliation at an academic medical center: Implementation of a comprehensive program from admission to discharge. Am J Health Syst Pharm 66:2126-2131, 2009

32. Ponniah A, Anderson B, Shakib S, et al: Pharmacists' role in the post-discharge management of patients with heart failure: A literature review. J Clin Pharm Ther 32:343-352, 2007

33. Ellitt GR, Brien JE, Aslani P, et al: Quality patient care and pharmacists' role in its continuity: A systematic review. Ann Pharmacother 43:677-691, 2009

© 2015 by American Society of Clinical Oncology 1459

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Evaluation of a Pharmacist-Led Medication Assessment Used to Identify Prevalence of and Associations With Polypharmacy and Potentially Inappropriate Medication Use Among Ambulatory Senior Adults With Cancer

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

Ginah Nightingale No relationship to disclose

Emily Hajjar Honoraria: Prime Therapeutics, Kaplan Medical Travel, Accommodations, Expenses: Prime Therapeutics, Kaplan

Kristine Swartz No relationship to disclose

Jocelyn Andrel-Sendecki Employment: Janssen Pharmaceuticals

Andrew Chapman No relationship to disclose

Appendix

Comorbidity	No PP (< 5 medications) (n = 37)		medi	PP (≥ 5 cations) = 197)		media	and < 10 cations) = 96)	medic	(≥ 10 ations) 101)	
Туре	No.	%	No.	%	Р	No.	%	No.	%	Р
Cardiovascular	30	81.08	186	94.42	.012	86	89.6	100	99.0	.004
Endocrine	11	29.73	99	50.25	.030	41	42.7	58	57.4	.046
GI	8	21.62	97	49.24	.002	43	44.8	54	53.5	.25
Hematologic	9	24.32	69	35.03	.256	29	30.2	40	39.6	.18
Neurologic	6	16.22	77	36.09	.008	37	38.5	40	39.6	.88
Nutritional	7	18.92	29	14.72	.468	12	12.5	17	16.8	.42
Ophthalmologic	7	18.92	84	42.64	.006	35	36.5	49	48.5	.11
Psychiatric	12	32.43	76	38.58	.580	31	32.3	45	44.6	.08
Renal	3	8.11	40	20.30	.104	12	12.5	28	27.7	.00
Respiratory	5	13.51	79	40.10	.002	32	33.3	47	46.5	.08
Rheumatologic	21	56.76	125	63.45	.463	57	59.4	68	67.3	.30
Urologic	3	8.11	63	31.98	.002	26	27.1	37	36.6	.17

Comorbidity Type	No PIM	No PIM (n $=$ 115)		PIM (n = 119)		
	No.	%	No.	%	Р	
Cardiovascular	101	87.8	115	96.6	.014	
Endocrine	57	49.6	53	44.5	.513	
GI	42	36.5	63	52.9	.013	
Hematologic	42	36.5	36	30.3	.334	
Neurologic	32	27.8	51	42.9	.020	
Nutritional	22	19.1	14	11.8	.147	
Ophthalmologic	48	41.7	43	36.1	.422	
Psychiatric	29	25.2	59	49.6	< .001	
Renal	22	19.1	21	17.7	.866	
Respiratory	38	33.0	46	38.7	.414	
Rheumatologic	72	62.6	74	62.2	1.000	
Urologic	33	28.7	33	27.7	.886	

Abbreviation: PIM, potentially inappropriate medication.

© 2015 by American Society of Clinical Oncology Information downloaded from jco.ascopubs.org and provided by at THOMAS JEFFERSON UNIVERSITY on August 10, Copyright © 2015 America01 Society14f7Clift0c2880n6ology. All rights reserved.

Nightingale et al




Fig A1. Rate of potentially inappropriate medication (PIM) use between polypharmacy categories.